## Albert Altés

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10750960/publications.pdf

Version: 2024-02-01

858243 721071 21 691 12 23 h-index citations g-index papers 24 24 24 958 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12Âyears follow-up of a phase 2 trial. Annals of Hematology, 2017, 96, 639-646.	0.8	7
2	Hereditary hemochromatosis. Problems in diagnosis and treatment. Medicina ClÃnica (English Edition), 2015, 144, 424-428.	0.1	0
3	Detection of hereditary hemochromatosis and biochemical iron overload in primary care: A multicenter case finding study in Spain. American Journal of Hematology, 2010, 85, 294-296.	2.0	6
4	Does the SLC40A1 gene modify HFE-related haemochromatosis phenotypes?. Annals of Hematology, 2009, 88, 341-345.	0.8	16
5	Mutations in HAMP and HJV genes and their impact on expression of clinical hemochromatosis in a cohort of 100 Spanish patients homozygous for the C282Y mutation of HFE gene. Annals of Hematology, 2009, 88, 951-955.	0.8	16
6	Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication. Clinical Cancer Research, 2008, 14, 155-161.	3.2	117
7	High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. Haematologica, 2008, 93, 207-214.	1.7	24
8	Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy. Anti-Cancer Drugs, 2007, 18, 821-825.	0.7	12
9	Early clinical impact of iron overload in stem cell transplantation. A prospective study. Annals of Hematology, 2007, 86, 443-447.	0.8	58
10	The relationship between iron overload and clinical characteristics in a Spanish cohort of 100 C282Y homozygous hemochromatosis patients. Annals of Hematology, 2007, 86, 831-835.	0.8	11
11	Genotype–phenotype correlation in a Spanish population homozygous for the H63D mutation of the HFE gene. Annals of Hematology, 2006, 85, 340-342.	0.8	23
12	The relationship between transferrin saturation and erythropoiesis during stem cell transplantation. Haematologica, 2006, 91, 992-3.	1.7	3
13	Prevalence of the C282Y, H63D, and S65C Mutations of the HFEGene in 1,146 Newborns from a Region of Northern Spain. Genetic Testing and Molecular Biomarkers, 2004, 8, 407-410.	1.7	33
14	Single nucleotide polymorphism in the 5′ tandem repeat sequences ofthymidylate synthasegene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. International Journal of Cancer, 2004, 112, 733-737.	2.3	118
15	Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. British Journal of Haematology, 2002, 119, 976-984.	1.2	163
16	Bacteremia by Gram-Negative Bacilli in Patients with Hematologic Malignancies. Acta Haematologica, 1999, 102, 7-11.	0.7	18
17	Hematopoietic growth factor (G-CSF or GM-CSF) after salvage chemotherapy in refractory or relapsed adult de novo acute leukemia. Leukemia and Lymphoma, 1996, 20, 321-326.	0.6	3
18	Heparin-induced thrombocytopenia and heart operation: Management with tedelparin. Annals of Thoracic Surgery, 1995, 59, 508-509.	0.7	26

## Albert Altés

#	Article	IF	CITATIONS
19	Reply. Annals of Thoracic Surgery, 1995, 60, 1160-1161.	0.7	1
20	<i>Capnocytophaga</i> Bacteremia in Neutropenic Patients: Report of Two Cases. Acta Haematologica, 1994, 92, 46-47.	0.7	2
21	Treatment of Refractory and Relapsed Adult Acute Leukemia Using a Uniform Chemotherapy Protocol. Leukemia and Lymphoma, 1993, 11, 393-398.	0.6	7